search
Back to results

Clinical Outcomes From Nalmefene (COINED)

Primary Purpose

Opioid Overdose

Status
Withdrawn
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
Nalmefene Hydrochloride Injection
Naloxone Hydrochloride Injection
Sponsored by
Purdue Pharma LP
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Opioid Overdose

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Presumed or known opioid overdose in community settings. Experiencing clinically significant respiratory depression based on appropriate medical judgement. Patient airway is open and unobstructed at the time of enrollment. (Utilization of oral pharyngeal or nasal pharyngeal airway is allowed.) Pre-hospital naloxone administration is allowed. Exclusion Criteria: Patient age known or estimated to be less than 18 years. Patient has one or more additional documented acute medical, traumatic, toxicologic, or psychiatric conditions that would extend length of treatment or adversely alter the clinical outcome. Cardiac arrest, secondary to opioid intoxication. Arrested, jailed, or imprisoned patients. Inappropriate for the study per judgement of research team.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Nalmefene

    Naloxone

    Arm Description

    Nalmefene hydrochloride (HCl) injection

    Naloxone hydrochloride (HCl) injection

    Outcomes

    Primary Outcome Measures

    Reversal of Respiratory Depression
    Normalization of the end tidal carbon dioxide value (if measured) to between 35 and 45 mmHg and/or ≥5 breaths per minute increase in respiratory rate from baseline (pre-dose) measurement, with rate of at least 12 breaths per minute.

    Secondary Outcome Measures

    Time to Reversal from administration of opioid antagonist
    Recurrence of Respiratory Depression
    Increased end tidal carbon dioxide value (if measured) above 45 mmHg when previously within the normal range and/or ≥5 breaths per minute decrease in respiratory rate from maximum post-reversal measurement, with a rate of at most 12 breaths per minute.
    ED Disposition
    One of the following will apply: ED Discharge Hospital Admission ICU Admission Left against medical advice Transfer to another facility Death.
    Drug Dosing
    Dose administered for each opioid antagonist given to patients during their ED encounter - Individual dose amount and frequency Cumulative dose Any pre-hospital naloxone given prior to ED arrival - Dose amount, route
    Richmond-Agitation Sedation Scale (RASS) Score
    This is a single-item instrument used to quickly assess the degree of patient alertness and agitation in emergency and critical care settings. It is an observational assessment conducted by healthcare providers, and it can be completed in seconds. The scale uses integers from -5 to +4, each with its own clear anchor. A score of 0 means that the patient is alert and calm. Negative integers indicate diminished responsiveness and consciousness, with -1 indicating that a patient will open their eyes or make eye contact for 10 or more seconds when awakened by voice, and -5 meaning that the patient is unarousable by voice or physical stimulation. Positive integers indicate an increased level of arousal or agitation. The positive end of the scale spans from +1 (anxious, apprehensive, but not aggressive) to +4 (combative, violent, danger to staff).
    Clinical Opioid Withdrawal Scale (COWS) Score
    This is an observational assessment performed by a clinician to diagnose and assess the severity of opioid withdrawal symptoms. Eleven different opioid withdrawal symptoms are included in the COWS. The clinician will score the presence and severity of each symptom, with 0 indicating that the symptom is absent and more severe symptoms warranting a higher score. Individual symptom scores are then added to determine the overall severity of the patient's withdrawal. Total scores range from 5 to 48 where 5 - 12 = mild; 13 - 24 = moderate; 25 - 36 moderately severe; and greater than 36 = severe withdrawal.
    Oxygen saturation level
    Pulse oximetry monitoring will be used to assess the patient's oxygen saturation level (SpO2), expressed as a percentage from 0 to 100.
    Length of time during ED encounter
    Defined as the difference between time at Triage to time at ED Disposition

    Full Information

    First Posted
    March 15, 2023
    Last Updated
    July 10, 2023
    Sponsor
    Purdue Pharma LP
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT05808881
    Brief Title
    Clinical Outcomes From Nalmefene
    Acronym
    COINED
    Official Title
    Clinical Outcomes From Injectable Nalmefene in the Emergency Department (COINED)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    July 2023
    Overall Recruitment Status
    Withdrawn
    Why Stopped
    Due to changes in research objectives and methodological approach.
    Study Start Date
    June 2023 (Anticipated)
    Primary Completion Date
    May 2024 (Anticipated)
    Study Completion Date
    May 2024 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Purdue Pharma LP

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    Yes
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    The purpose of this study is to assess the effectiveness of nalmefene relative to naloxone for the reversal of opioid intoxication in emergency department (ED) settings.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Opioid Overdose

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    0 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Nalmefene
    Arm Type
    Experimental
    Arm Description
    Nalmefene hydrochloride (HCl) injection
    Arm Title
    Naloxone
    Arm Type
    Active Comparator
    Arm Description
    Naloxone hydrochloride (HCl) injection
    Intervention Type
    Drug
    Intervention Name(s)
    Nalmefene Hydrochloride Injection
    Intervention Description
    for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
    Intervention Type
    Drug
    Intervention Name(s)
    Naloxone Hydrochloride Injection
    Other Intervention Name(s)
    Narcan
    Intervention Description
    for intravenous/intramuscular/subcutaneous (IV/IM/SC) administration
    Primary Outcome Measure Information:
    Title
    Reversal of Respiratory Depression
    Description
    Normalization of the end tidal carbon dioxide value (if measured) to between 35 and 45 mmHg and/or ≥5 breaths per minute increase in respiratory rate from baseline (pre-dose) measurement, with rate of at least 12 breaths per minute.
    Time Frame
    Up to 3 hours
    Secondary Outcome Measure Information:
    Title
    Time to Reversal from administration of opioid antagonist
    Time Frame
    Up to 3 hours
    Title
    Recurrence of Respiratory Depression
    Description
    Increased end tidal carbon dioxide value (if measured) above 45 mmHg when previously within the normal range and/or ≥5 breaths per minute decrease in respiratory rate from maximum post-reversal measurement, with a rate of at most 12 breaths per minute.
    Time Frame
    Up to 3 hours
    Title
    ED Disposition
    Description
    One of the following will apply: ED Discharge Hospital Admission ICU Admission Left against medical advice Transfer to another facility Death.
    Time Frame
    Up to 3 hours
    Title
    Drug Dosing
    Description
    Dose administered for each opioid antagonist given to patients during their ED encounter - Individual dose amount and frequency Cumulative dose Any pre-hospital naloxone given prior to ED arrival - Dose amount, route
    Time Frame
    Up to 3 hours
    Title
    Richmond-Agitation Sedation Scale (RASS) Score
    Description
    This is a single-item instrument used to quickly assess the degree of patient alertness and agitation in emergency and critical care settings. It is an observational assessment conducted by healthcare providers, and it can be completed in seconds. The scale uses integers from -5 to +4, each with its own clear anchor. A score of 0 means that the patient is alert and calm. Negative integers indicate diminished responsiveness and consciousness, with -1 indicating that a patient will open their eyes or make eye contact for 10 or more seconds when awakened by voice, and -5 meaning that the patient is unarousable by voice or physical stimulation. Positive integers indicate an increased level of arousal or agitation. The positive end of the scale spans from +1 (anxious, apprehensive, but not aggressive) to +4 (combative, violent, danger to staff).
    Time Frame
    Up to 3 hours
    Title
    Clinical Opioid Withdrawal Scale (COWS) Score
    Description
    This is an observational assessment performed by a clinician to diagnose and assess the severity of opioid withdrawal symptoms. Eleven different opioid withdrawal symptoms are included in the COWS. The clinician will score the presence and severity of each symptom, with 0 indicating that the symptom is absent and more severe symptoms warranting a higher score. Individual symptom scores are then added to determine the overall severity of the patient's withdrawal. Total scores range from 5 to 48 where 5 - 12 = mild; 13 - 24 = moderate; 25 - 36 moderately severe; and greater than 36 = severe withdrawal.
    Time Frame
    Up to 3 hours
    Title
    Oxygen saturation level
    Description
    Pulse oximetry monitoring will be used to assess the patient's oxygen saturation level (SpO2), expressed as a percentage from 0 to 100.
    Time Frame
    Up to 3 hours
    Title
    Length of time during ED encounter
    Description
    Defined as the difference between time at Triage to time at ED Disposition
    Time Frame
    Up to 3 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Presumed or known opioid overdose in community settings. Experiencing clinically significant respiratory depression based on appropriate medical judgement. Patient airway is open and unobstructed at the time of enrollment. (Utilization of oral pharyngeal or nasal pharyngeal airway is allowed.) Pre-hospital naloxone administration is allowed. Exclusion Criteria: Patient age known or estimated to be less than 18 years. Patient has one or more additional documented acute medical, traumatic, toxicologic, or psychiatric conditions that would extend length of treatment or adversely alter the clinical outcome. Cardiac arrest, secondary to opioid intoxication. Arrested, jailed, or imprisoned patients. Inappropriate for the study per judgement of research team.

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Clinical Outcomes From Nalmefene

    We'll reach out to this number within 24 hrs